The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2018 | Advancing lung cancer therapy: from palliative chemotherapy to immunotherapy
James Spicer, FCRP, PhD, MRCP, MBBS, of the Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discusses the value of PD-L1 in lung cancer treatment, after highlighting the rapid progress that has been made in therapeutics for lung cancer, where previously, palliative chemotherapy was the only stand-alone treatment option. Speaking from the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, Professor Spicer, points out that PD-L1 is the most well known biomarker to help guide lung cancer immunotherapy.
